FDA Class II Recall: Otsuka ICU Medical LLC Withdraws 509,360 Units of Sodium Chloride Injection Over Sterility Concerns
Otsuka ICU Medical LLC has initiated a Class II recall of 509,360 units of 0.9% Sodium Chloride Injection, USP, 100 mL, distributed nationwide in the USA. The recall, impacting Lot # 1029921, stems from a lack of sterility assurance due to potential flexible container leaks. Procurement and supply chain teams must immediately assess inventory and secure alternative sources for this critical intravenous solution.
FDA Class II Recall: Sterility Breach Impacts Otsuka ICU Medical LLC's Sodium Chloride Supply
Otsuka ICU Medical LLC has initiated a Class II recall, designated D-0143-2026, for 509,360 units of 0.9% SODIUM CHLORIDE Injection, USP, 100 mL. This critical regulatory action, commenced on October 27, 2025, is a direct response to a significant quality concern: a lack of assurance of sterility, specifically citing the potential for flexible container leaks. The affected product, manufactured by ICU Medical Inc. in Lake Forest, Illinois, carries Lot # 1029921 with an expiration date of February 28, 2027. This nationwide recall in the USA mandates immediate attention from procurement directors and supply chain VPs. The presence of container leaks directly compromises the sterile barrier, introducing a serious risk of microbial contamination for an intravenous product. For your business, this means an immediate halt to the distribution and use of any affected product in your inventory. Regulatory affairs heads must ensure compliance with recall instructions, including quarantine and return procedures, to mitigate patient safety risks and avoid further regulatory exposure. The sheer volume of recalled units underscores the potential for a significant, albeit temporary, disruption in the supply of a foundational medical solution.
Critical Product Profile: 0.9% Sodium Chloride Injection from ICU Medical Inc.
The recalled product, 0.9% SODIUM CHLORIDE Injection, USP, 100 mL, is a fundamental and high-volume intravenous solution manufactured by ICU Medical Inc., based in Lake Forest, Illinois, USA. This product, identified by NDA018090 and various product NDCs including 0990-7984-37, is essential for a multitude of clinical applications, including patient hydration, electrolyte balance, and as a diluent for other injectable medications. Its widespread use across hospitals, clinics, and other healthcare facilities makes any disruption to its supply a critical concern for patient care continuity. For procurement directors, understanding the manufacturer's broader portfolio and market share for such staple products is crucial. ICU Medical Inc. is a significant player in the medical device and pharmaceutical sectors, and issues with core products like Sodium Chloride Injection can have ripple effects across their entire supply chain and customer base. Business development executives should note the competitive landscape for essential injectables, where quality and supply reliability are paramount differentiators. This event highlights the vulnerability of relying heavily on a single supplier for such indispensable medicines.
Supply Chain Vulnerability: Nationwide Exposure to Sodium Chloride Shortages
The distribution pattern for the recalled 0.9% SODIUM CHLORIDE Injection is explicitly stated as "Distributed Nationwide in the USA." With 509,360 100 mL bags affected from a single lot (Lot # 1029921), this recall presents a substantial, immediate supply chain challenge across the entire United States healthcare system. Supply chain VPs must recognize that this volume represents a significant portion of a critical, high-turnover product. Hospitals, group purchasing organizations (GPOs), and wholesale distributors that source from Otsuka ICU Medical LLC or ICU Medical Inc. are directly impacted. The potential for flexible container leaks leading to sterility issues means that even seemingly minor defects can have widespread consequences for patient safety and treatment protocols. This situation necessitates an urgent review of current inventory levels, consumption rates, and existing contracts for 0.9% Sodium Chloride. The commercial implication is clear: a sudden reduction in available supply can lead to price volatility, allocation challenges, and, in severe cases, rationing of an essential medicine. Proactive communication with downstream partners and a rapid assessment of alternative supply channels are imperative to mitigate operational disruptions and maintain patient care standards.
Strategic Sourcing: Navigating Alternatives for Sterile Sodium Chloride Injectables
Given the nationwide recall of a critical intravenous solution, procurement teams must swiftly identify and qualify alternative suppliers for 0.9% Sodium Chloride Injection. While the provided intelligence does not name specific alternative suppliers, the market for generic sterile injectables typically includes major pharmaceutical manufacturers and specialized contract manufacturing organizations (CMOs) with robust sterile fill-finish capabilities. Companies like Baxter International, B. Braun Medical, and Fresenius Kabi are generally known for producing a range of intravenous solutions, though specific product availability and qualification status would need to be verified. Geographic diversity in sourcing is a crucial strategy to mitigate single-point-of-failure risks, even when the immediate recall is US-centric. However, qualifying new sterile injectable suppliers is a rigorous and time-consuming process, typically involving extensive audits, stability studies, and regulatory submissions that can span 6 to 18 months. Procurement directors should prioritize suppliers with existing FDA approvals for similar products and a proven track record of quality and supply reliability. Business development executives may also identify opportunities to partner with new suppliers or expand existing relationships to fill the market void created by this disruption, ensuring long-term supply resilience.
Regulatory Compliance Landscape: ICU Medical Inc.'s Current Event in Context
The provided intelligence does not indicate a history of prior FDA Warning Letters, 483s, or Import Alerts specifically for ICU Medical Inc. or Otsuka ICU Medical LLC related to their manufacturing facilities or products. However, the current Class II recall for 0.9% Sodium Chloride Injection due to sterility concerns and potential container leaks is a significant regulatory event that will draw intense FDA scrutiny. This incident occurs within a broader industry context, as evidenced by a parallel event in June 2026 involving Essential Wellness Pharma's Progesterone Injection, also subject to an FDA Class II recall for failing sterility assurance. This trend underscores persistent challenges in maintaining robust quality systems for sterile products across the pharmaceutical sector. For regulatory affairs heads, this recall signals the critical importance of a comprehensive quality management system, particularly for sterile manufacturing processes. The FDA will expect a thorough root cause investigation and the implementation of effective corrective and preventive actions (CAPAs). An inadequate response or a recurrence of similar issues could escalate regulatory actions, potentially impacting other products or facilities.
Forward Outlook: Remediation, Reinspection, and Future Supply Stability
The status of this recall (D-0143-2026) is currently "Ongoing," indicating that Otsuka ICU Medical LLC is actively managing the product retrieval and investigation process. Following the firm-initiated notification via letter, the FDA will closely monitor the effectiveness of the recall and the company's remediation efforts. Key actions required from the recalling firm include a comprehensive root cause analysis for the flexible container leaks and the lack of sterility assurance, followed by the implementation of robust corrective and preventive actions (CAPAs). This will likely involve process improvements, equipment upgrades, and enhanced quality control measures at the ICU Medical Inc. manufacturing facility in Lake Forest, Illinois. A reinspection by the FDA is highly probable to verify the adequacy of these CAPAs. For supply chain VPs, this means anticipating potential extended disruptions in the supply of 0.9% Sodium Chloride Injection from this manufacturer. The timeline for full resolution and restoration of confidence in supply can be lengthy, depending on the complexity of the issues and the FDA's satisfaction with the remediation. Business development executives should consider the long-term market implications, as this event may prompt healthcare providers to diversify their sourcing strategies for essential sterile injectables to enhance supply chain resilience.